About us

E25Bio revolves around an idea that technology that saves lives is in fact simple.
Our goal is to predict outbreaks around the world and help control them using unique and affordable testing solutions.

We've managed to develop an investigational SARS and SARS-CoV-2 rapid tests in 3 weeks

2020

jan

30

SARS-CoV-2 is a PHEIC

2020

feb

06

E25Bio high-throughput screen of existing mAbs

2020

feb

26

E25Bio develops SARS-CoV-2 rapid test

2020

mar

20

E25Bio partners with top academic Boston hospitals for scaled evaluation and production

After FDA EUA

Future
launch of rapid tests

After FDA EUA

Future
launch of rapid tests

Meet the team

Of scientists who invented and are developing an inexpensive yet accurate means of testing for COVID-19 and the people making it happen

Irene Bosch, PhD

Co-founder & CTO


View full bio

Bobby Brooke Herrera, PhD

Co-founder & CEO


View full bio

Enrique Shadah, MBA

COO/CFO


View full bio

Lee Gehrke, PhD

Co-founder/Scientific Advisory Board


View full bio

Nol Salcedo, MSc

Scientist


View full bio

Adam Gomez, MSc

Scientist


View full bio

Ankita Reddy, BSc

Scientist


View full bio

Edward Segel, MBA

Advisor


View full bio

Helena Del Corral, PhD

Strategic Business Development, Colombia


Carlos-Henri Ferré, MA

Director of Operations and Communications


View full bio

Nik Lal

Design Engineer


View full bio

Our investors

 

Without them, E25Bio wouldn’t be what it is today. So, the least we can do is to mention them.

Special thanks to the scientific advisory board

 

Lee Gerke (PhD), Jennifer Bender (PhD), Phyllis Kanki (PhD), Michael Diamond (MD, PhD), Jonathan Dinsmore (PhD), Jason Prapas (PhD).